Year All202520242023202220212020201920182017 Inozyme Pharma Appoints Kevin B. Johnson, Ph.D., MBA, as Senior Vice President, Regulatory Affairs Nov 09, 2020 Inozyme Pharma Appoints Yves Sabbagh, Ph.D., as Senior Vice President and Chief Scientific Officer Oct 13, 2020 Inozyme Pharma Reports Second Quarter 2020 Financial Results and Provides Business Highlights Sep 03, 2020 Inozyme Pharma Announces Closing of Initial Public Offering and Full Exercise by Underwriters of Option to Purchase Additional Shares Jul 30, 2020 Inozyme Pharma Announces Pricing of Initial Public Offering Jul 23, 2020 Inozyme Pharma Acquires ENPP1 Deficiency Program Assets from Alexion Pharmaceuticals Jul 17, 2020 Inozyme Pharma Announces Changes to its Board of Directors Jun 16, 2020 Inozyme Pharma and GACI Global Initiate Patient Burden of Disease Study to Improve the Understanding of the Severity and Impact of Disease in Patients with ENPP1 Deficiency and ABCC6 Deficiency May 14, 2020 Inozyme Pharma Expands Medical Leadership Team Nov 14, 2019 Inozyme Pharma Raises $67 Million in Series A2 Financing to Develop Therapies for Rare Mineralization Disorders Apr 10, 2019
Year All202520242023202220212020201920182017 Inozyme Pharma Appoints Kevin B. Johnson, Ph.D., MBA, as Senior Vice President, Regulatory Affairs Nov 09, 2020 Inozyme Pharma Appoints Yves Sabbagh, Ph.D., as Senior Vice President and Chief Scientific Officer Oct 13, 2020 Inozyme Pharma Reports Second Quarter 2020 Financial Results and Provides Business Highlights Sep 03, 2020 Inozyme Pharma Announces Closing of Initial Public Offering and Full Exercise by Underwriters of Option to Purchase Additional Shares Jul 30, 2020 Inozyme Pharma Announces Pricing of Initial Public Offering Jul 23, 2020 Inozyme Pharma Acquires ENPP1 Deficiency Program Assets from Alexion Pharmaceuticals Jul 17, 2020 Inozyme Pharma Announces Changes to its Board of Directors Jun 16, 2020 Inozyme Pharma and GACI Global Initiate Patient Burden of Disease Study to Improve the Understanding of the Severity and Impact of Disease in Patients with ENPP1 Deficiency and ABCC6 Deficiency May 14, 2020 Inozyme Pharma Expands Medical Leadership Team Nov 14, 2019 Inozyme Pharma Raises $67 Million in Series A2 Financing to Develop Therapies for Rare Mineralization Disorders Apr 10, 2019
Inozyme Pharma Appoints Kevin B. Johnson, Ph.D., MBA, as Senior Vice President, Regulatory Affairs Nov 09, 2020
Inozyme Pharma Appoints Yves Sabbagh, Ph.D., as Senior Vice President and Chief Scientific Officer Oct 13, 2020
Inozyme Pharma Reports Second Quarter 2020 Financial Results and Provides Business Highlights Sep 03, 2020
Inozyme Pharma Announces Closing of Initial Public Offering and Full Exercise by Underwriters of Option to Purchase Additional Shares Jul 30, 2020
Inozyme Pharma and GACI Global Initiate Patient Burden of Disease Study to Improve the Understanding of the Severity and Impact of Disease in Patients with ENPP1 Deficiency and ABCC6 Deficiency May 14, 2020
Inozyme Pharma Raises $67 Million in Series A2 Financing to Develop Therapies for Rare Mineralization Disorders Apr 10, 2019